Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up

• Published in: International journal of colorectal disease 2008-06, Vol.23 (6), p.595-600
• Main Authors: Suppiah, A., Alabi, A., Madden, L., Hartley, J. E., Monson, J. R. T., Greenman, J.
• Format: Article
• Language: English
• Subjects: Aged; Autoantibodies - blood; Biological and medical sciences; Biomarkers, Tumor - blood; Colorectal cancer; Colorectal Neoplasms - immunology; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Enzyme-Linked Immunosorbent Assay; Female; Gastroenterology; Gastroenterology. Liver. Pancreas. Abdomen; Hepatology; Humans; Internal Medicine; Male; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Original Article; Proctology; Prognosis; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Surgery; Survival Rate; Tumor Suppressor Protein p53 - immunology; Tumors
• ISSN: 0179-1958; 1432-1262
• DOI: 10.1007/s00384-008-0458-4

Background The prognostic significance of anti-53 autoantibody in colorectal cancer (CRC) patients is unclear due to measurement of overall rather than disease-specific survival and generally short follow-up periods in many studies. We aim to investigate prognostic significance of anti-p53 auto-antibodies in a study with long-term follow-up (minimum 5 years). Methods ELISA for anti-p53 autoantibody was assayed in serum from 92 patients with CRC and 28 controls. Results Anti-p53 autoantibody was found in 20 patients (21.7%) and none of the controls. No difference in Dukes’ (A/B vs. C/D), Stage (I/II vs. III/IV), T1/2 vs. T3/4, N0 vs. N1/2, M0 vs. M1, poor vs. well/moderate differentiation and proximal vs. distal CRC was observed. Median overall survival was 62 months and median disease-specific survival was 73 months. Dukes’ C/D, Stage III/IV, N1/2 and M1 were associated with poor disease-specific survival in univariate analysis. Stage III/IV was an independent prognostic factor in overall and disease-free survival in multivariate analysis. Anti-p53 autoantibody sero-positivity did not influence overall ( p  = 0.980) or disease-specific survival ( p  = 0.874). Median overall survival in anti-p53 autoantibody positive patients was 62 months vs. 60 months in anti-53 autoantibody negative patients. Median disease-specific survival in anti-p53 autoantibody positive patients was 73 months vs. 82 months. Conclusion Anti-p53 autoantibody is not related to clinical parameters of CRC and has no prognostic significance in long-term follow-up.